Eli Lilly (LLY): FY25 Q3 earnings call, Oct 30, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
9 matches for “Impact”; 5 quoted, at least 25 words apart.
…products more than doubled as our medicines continued to increase their global impact. In the U.S., Lilly gained market share in the incretin analogs market…
…onetime benefit related to a milestone payment and business development. Excluding this impact, revenue grew 81% in constant currency. Japan, China and Rest of the…
…in Q3 2025 compared to the same period last year. While the impact of the CVS template formulary change was disruptive to patients and physicians,…
…2025 financial results. Based on the strong underlying performance and the favorable impact of foreign exchange rates, we are increasing the midpoint of our revenue…
…study is the first of its kind. It's designed to measure the impact of switching from injectable semaglutide or injectable tirzepatide to oral orforglipron. Our…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP